Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab, Lenvatinib, and SOX in Advanced Gastric Cancer
NCT06277024Phase 2Recruiting
- Sponsor
- Fujian Medical University
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and lenvatinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fujian Medical University. Primary endpoint: Objective Response Rate at 3 years. Started Jan 2023; status: recruiting.
02
Drugs
cadonilimablenvatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06277024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277024.